Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Harvard Bioscience ( (HBIO) ) just unveiled an update.
On January 19, 2026, Harvard Bioscience’s Board of Directors approved an amendment to the company’s Amended and Restated By-laws that lowers the quorum requirement for stockholder meetings from a majority to one-third of the shares entitled to vote. The change, which took effect immediately upon Board approval, is expected to make it easier for the company to achieve quorum at shareholder meetings, potentially streamlining corporate governance processes and facilitating timely decision-making for investors and management.
The most recent analyst rating on (HBIO) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.
Spark’s Take on HBIO Stock
According to Spark, TipRanks’ AI Analyst, HBIO is a Neutral.
The score is held back primarily by weak financial performance (declining revenue, losses, and leverage), with only partial support from improving cash flow. The earnings call was a relative positive—showing margin/EBITDA improvement, cost discipline, better cash generation, and debt reduction—but technical indicators remain soft and valuation is not informative due to negative earnings.
To see Spark’s full report on HBIO stock, click here.
More about Harvard Bioscience
Harvard Bioscience, Inc. is a life sciences tools company that develops and supplies specialized instruments, systems, and technologies used in biological and medical research, serving academic, pharmaceutical, and biotechnology customers worldwide.
Average Trading Volume: 6,415,331
Technical Sentiment Signal: Sell
Current Market Cap: $26.18M
See more data about HBIO stock on TipRanks’ Stock Analysis page.